Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Hydromethylthionine mesylate (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LUCIDITY
- Sponsors TauRx Pharmaceuticals
- 07 Mar 2024 Results presented in a TauRx Pharmaceuticals Media Release.
- 05 Feb 2024 According to a TauRx Pharmaceuticals media release, 24-month data from this trial will be presented at the upcoming AD/PD 2024 Alzheimers & Parkinsons Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
- 16 Jul 2023 According to a TauRx Pharmaceuticals media release, TauRx is preparing publications to report both the NfL data and the full 24-month data.